MUC16 and ovarian carcinoma: When antibody-loaded paclitaxel nanoparticles and anti-MUC16 nanomicelles have been used to target mesothelin and MUC16 (CA125), ovarian cancer targeting ability and tumour uptake were increased, and systemic toxicity was reduced [96,97].